Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study

Clinical Cancer Research

Volumn 8, Issue 11, 2002, Pages 3401-3406

  Colnot, David R ^a   Ossenkoppele, Gert J ^a   Roos, Jan C ^a   Quak, Jasper J ^a   De Bree, Remco ^a   Börjesson, Pontus K ^a   Huijgens, Peter C ^a   Snow, Gordon B ^a   Van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; MONOCLONAL ANTIBODY RE 186; MONOCLONAL ANTIBODY U36; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RHENIUM 186; UNCLASSIFIED DRUG; CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; RADIOISOTOPE; RHENIUM;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE MARROW TOXICITY; CLINICAL TRIAL; COLONY FORMING UNIT; DOSE RESPONSE; DOSIMETRY; DRUG TOLERABILITY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; ISOTOPE LABELING; MACROPHAGE; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; SQUAMOUS CELL CARCINOMA; BIOSYNTHESIS; BONE MARROW CELL; HEAD AND NECK TUMOR; MIDDLE AGED; PATHOLOGY; RADIATION EXPOSURE; RADIATION RESPONSE; RADIOMETRY; RECURRENT DISEASE; TIME; TISSUE DISTRIBUTION;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; BONE MARROW CELLS; CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOMETRY; RECURRENCE; RHENIUM; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0036845695     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Vose, J. M., Wahl, R. L., Saleh, M., Rohatiner, A. Z., Knox, S. J., Radford, J. A., Zelenetz, A. D., Tidmarsh, G. F., Stagg, R. J., and Kaminski, M. S. Multicenter Phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol., 18: 1316-1323, 2000.
2. Kaminski, M. S., Estes, J., Zasadny, K. R., Francis. I. R., Ross, C. W., Tuck, M., Regan, D., Fisher, S., Gutierrez, J., Kroll, S., Stagg, R., Tidmarsch, G., and Wahl, R. L. Radioimmunotherapy with iodine 131-I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood, 96: 1259-1266, 2000.
3. Liu, S. Y., Eary, J. F., Petersdorf, S. H., Martin, P. J., Maloney, D. G., Appelbaum, F. R., Matthews, D. C., Bush, S. A., Durack, L. D., Fisher, D. R., Gooley, T., Bernstein, I. D., and Press, O. W. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J. Clin. Oncol., 16: 3270-3278, 1998.
4. Richman, C. M., DeNardo, S. J., O'Grady, L. F., and DeNardo, G. L. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131-I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res., 55: 5916s-5920s, 1995.
5. Wong, J. Y., Somlo, G., Odom-Maryon, T., Williams, L. E., Liu, A., Yamauchi, D., Wu, A. M., Yazaki, P., Wilczynski, S., Shively, J. E., Forman, S., Doroshow, J. H., and Raubitschek, A. A. Initial clinical experience evaluating yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer. Clin. Cancer Res., 5: 3224s-3231s, 1999.
6. Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D. R., and Porter, B. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 329: 1219-1224, 1993.
7. Woll, P. J., Tatcher, N., Lomax, L., Hodgetts, J., Lee, S. M., Burt, P. A., Stout, R., Simms, T., Davies, R., and Pettengell, R. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: A randomized Phase II trial in small-cell lung cancer patients. J. Clin. Oncol., 19: 712-719, 2001.
8. Huijgens, P. C., Dekker-Van Roessel, H. M., Jonkhoff, A. R., Admiraal, G. C., Zweegman, S., Schuurhuis, G. J., and Ossenkoppele, G. J. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplant., 27: 925-931, 2001.
9. Pettengell, R., Woll, P. J., O'Connor, D. A., Dexter, T. M., and Testa, N. G. Viability of haemopoietic progenitors from whole blood, bone marrow and leucapheresis product: Effects of storage media, temperature and time. Bone Marrow Transplant., 14: 703-709, 1994.
10. Ossenkoppele, G. J., Schuurhuis, G. J., Jonkhoff, A. R., Drager, A. M., Westra, G., Oberink, J. W., Legdeur, M. C. J. C., De Kreuk, A. M., Zweegman, S., and Huijgens, P. C. G-CSF (filgrastim)-stimulated whole blood kept unprocessed at 4°C does support a beam-like regimen in bad-risk lymphoma. Bone Marrow Transplant., 18: 427-431, 1996.
11. Schuurhuis, G. J., Muijen, M. M., Oberink, J. W., de Boer, F., Ossenkoppele, G. J., and Broxterman, H. J. Large populations of non-clonogenic early apoptotic CD34-positive cells are present in frozenthawed peripheral blood stem cell transplants. Bone Marrow Transplant., 27: 487-498, 2001.
12. De Boer, F., Drager, A. M., Pinedo, H. M., Kessler, F. L., van der Wall, E., Jonkhoff, A. R., van der Lelie, J., Huijgens, P. C., Ossenkoppele, G. J., and Schuurhuis, G. J. Extensive early apoptosis in frozenthawed CD34-positive stem cells decreases threshold doses for haematological recovery after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant., 29: 249-255, 2002.
13. Pettengell, R., Woll, P. J., Tatcher, N., Dexter, T. M., and Testa, N. G. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopietic progenitors in whole blood. J. Clin. Oncol., 13: 148-156, 1995.
14. Raina, V., Sharma, A., Kumar, R., and Bhargava, M. Whole blood harvested after granulocyte-colony stimulating factor (Neupogen) mobilization, and reinfused unprocessed after high-dose melphalan treatment, accelerates hematopoietic recovery in patients with multiple myeloma. Cancer (Phila.), 77: 1073-1078, 1996.
15. Ossenkoppele, G. J., Schuurhuis, G. J., Jonkhoff, A. R., Van der Hem, K. G., Legdeur, M. C. J. C., Boot-Bakker, A., Westra, A. H., Drager, A. M., and Huijgens, P. C. High-dose Melphalan with reinfusion of unprocessed, G-CSF-primed whole blood is an effective and non-toxic therapy in multiple myeloma. Eur. J. Cancer, 32A: 2058-2063, 1996.
16. Colnot, D. R., Quak, J. J., Roos, J. C., Van Lingen, A., Wilhelm, A. J., Van Kamp, G. J., Huijgens, P. C., Snow, G. B., and Van Dongen G. A. M. S. Phase I therapy study of rhenium-186-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J. Nucl. Med., 41: 1999-2010, 2000.
17. Van Hal, N. L. W., Van Dongen, G. A. M. S., Rood-Knippels, E. M. C., Van der Valk, P., Snow, G. B., and Brakenhoff, R. H. Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous cell carcinoma, recognizes a CD44 isoform. Int. J. Cancer, 68: 520-527, 1996.
18. Heider, K-H., Dämmrich, J., Skroch-Angel, P., Müller-Hermelink, H-K., Vollmers, H. P., Herrlich, P., and Ponta, H. Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res., 53: 4197-4203, 1993.
19. Heider, K-H., Sproll, M., Susani, S., Patzelt, E., Beaumier, P. L., Ostermann, E., Ahorn, H., and Adolf, G. R. Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol. Immunother., 43: 245-253, 1996.
20. Shen, S., DeNardo, G. L., Sgouros, G., O'Donnell, R. T., and DeNardo, S. J. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J. Nucl. Med., 40: 2102-2106, 1999.
21. Cancer Therapy Evaluation Program, D. C. T. D. N. N. D. Common Toxicity Criteria, Version 2.0. http: //ctep.info.nih.gov/CTC3/ctc.htm., 1998.
22. De Bree, R., Kuik, D. J., Quak, J. J., Roos, J. C., Van den Brekel, M. W. M., Castelijns, J. A., Van Wagtendonk, F. W., Greuter H. N. J. M., Snow. G. B., and Van Dongen, G. A. M. S. The impact of tumour volume and other characteristics on uptake of radiolabelled monoclonal antibodies in tumour tissue of head and neck cancer patients. Eur. J. Nucl. Med., 25: 1562-1565, 1998.
23. Chatal, J-F., Saccavinni, J-C., Thedrez, P., Curtet, C., Kremer, M., Guerreau, D., Nolibe, D., Fumoleau, P., and Guillard, Y. Biodistribution of indium-111-labeled OC125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian cancers. Cancer Res., 49: 3087-3094, 1989.
24. de Kreuk, A. M., Jonkhoff, A. R., Zevenbergen, A., Hendriks, E. C., Schuurhuis, G. J., Ossenkoppele, G. J., Drager, A. M., van Oostveen, J. W., and Huijgens, P. C. Storage of unprocessed G-CSF-mobilized whole blood in a modified Leibovitz's L15 medium preserves clonogenic capacity for at least 7 days. Bone Marrow Transplant., 28: 145-155, 2001.